Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
Details : Aflibercept is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Wet Macular Degeneration.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 10, 2025
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EXG001-307
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Exegenesis Bio Presents Data from Phase 1/2 Trial Of EXG001-307 for SMA Type 1
Details : EXG001-307 features a novel AAV design with a pro-NS promoter and is under early-stage trials with patients for treating Spinal Muscular Atrophy Type I.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 25, 2024
Lead Product(s) : EXG001-307
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EXG102-031
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of EXG102-031 in Patients With wAMD (Everest)
Details : EXG102-031 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Wet Macular Degeneration.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 15, 2023
Lead Product(s) : EXG102-031
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EXG102-031
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EXG102-031 intraocular injection is a rAAV-based gene therapy expressing a therapeutic fusion protein that is able to bind/neutralize all known subtypes of VEGF and ANG2, which are known to stimulate abnormal blood vessel formation and vascular leakage i...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 18, 2023
Lead Product(s) : EXG102-031
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable